Date : 28 January 2026
Headquarter: United States
Latest Update: In April 2025, Medtronic plc, a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for placement within the right ventricle.
Headquarter: United States
Latest Update: In January 2025, Abbott entered into a strategic collaboration with AtaCor Medical to develop an investigational extravascular implantable cardioverter defibrillator (EV-ICD) system, with the goal to enhance the safety and effectiveness of therapy for patients at risk of sudden cardiac death.
Headquarter: United States
Latest Update: In July 2025, Boston Scientific Corporation (BSC) began informing clinicians of the potential for significantly increasing low-voltage shock impedance (LVSI) associated with shock coil calcification in RELIANCE™ defibrillation leads coated with expanded polytetrafluoroethylene.
Headquarter: Germany
Latest Update: Recent research suggested shorter-than-expected battery life for BIOTRONIK tools, prompting a significant internal analysis.
Headquarter: China
Latest Update: In December 2025, MicroPort Scientific Corporation announced that the strategic merger between its subsidiaries MicroPort CardioFlow Medtech Corporation and MicroPort Cardiac Rhythm Management had been approved by MicroPort CardioFlow’s shareholders.
Headquarter: Netherlands
Latest Update: In January 2025, Royal Philips, a worldwide leader in health technology, announced that it had signed an agreement to sell its Emergency Care business.
The global defibrillator market size was estimated at USD 8.6 billion in 2025 and is predicted to increase from USD 9.29 billion in 2026 to approximately USD 18.8 billion by 2035, expanding at a CAGR of 8.14% from 2026 to 2035.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
Speak with a healthcare analyst about your research, consulting, or platform needs.